Corticosteroids and Glaucoma Risk

@article{Tripathi1999CorticosteroidsAG,
  title={Corticosteroids and Glaucoma Risk},
  author={R. Tripathi and S. Parapuram and B. Tripathi and Y. Zhong and K. Chalam},
  journal={Drugs \& Aging},
  year={1999},
  volume={15},
  pages={439-450}
}
Corticosteroids (glucocorticoids), used frequently as potent anti-inflammatory agents, increase the risk of glaucoma by raising the intraocular pressure (IOP) when administered exogenously (topically, periocularly or systemically) and in certain conditions of increased endogenous production (e.g. Cushing’s syndrome). Approximately 18 to 36% of the general population are corticosteroid responders. This response is increased to 46 to 92% in patients with primary open-angle glaucoma (POAG… Expand
Steroid-Induced Iatrogenic Glaucoma
TLDR
High-risk patients who receive steroids should be monitored closely and if they develop elevated IOP, steroids with lower potency or steroid-sparing agents should be used and the IOP usually returns to normal within 2–4 weeks after stopping the steroid. Expand
Commentary: Blindness from glaucoma associated with steroid abuse in children
TLDR
Although prolonged and sometimes indiscriminate use of steroids causes IOP rise and glaucomatous visual field loss, it is not unknown to encounter significant IOP elevation within hours of use, and this adverse effect of steroid use may not be reversible in certain susceptible individuals. Expand
[Drug-induced glaucoma].
TLDR
In cases when the patient's IOP does not normalize after discontinuation of steroids or when they must continue to take corticosteroids, the administration of topical drugs for the treatment of glaucoma should be considered. Expand
A review of systemic medications that may modulate the risk of glaucoma
TLDR
This review provides a summary of reported associations between different systemic medications and the risk of developing glaucoma or experiencing disease progression. Expand
Inhaled corticosteroids: Ocular safety and the hypothalamic-pituitary-adrenal axis.
  • W. Carr, S. Szefler
  • Medicine
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2016
TLDR
Because of systemic effects on the HPA axis, high doses of ICS should be avoided where possible and adult patients undergoing high-dose or long-term ICS therapy should be monitored for cataracts. Expand
Intraocular Pressure Effects of Common Topical Steroids for Post-Cataract Inflammation: Are They All the Same?
TLDR
The proportion of patients exhibiting an increase of ≥10 mmHg IOP in clinical studies has emerged as the most clinically relevant parameter for ophthalmologists to consider when deciding on which topical corticosteroid to use. Expand
Cutaneous corticosteroid-induced glaucoma
TLDR
The ability of certain topically applied corticosteroids to raise intra-ocular pressure (IOP) in susceptible individuals, particularly in open angle glaucoma patients, require care in the ophthalmologic and dermatologic practice. Expand
Corticosteroids and Open-Angle Glaucoma in the Elderly
TLDR
None of the classes of steroids were associated with the incidence of OAG in this elderly population, and associations between the use of corticosteroids and incident OAG were assessed using logistic regression models. Expand
Visual loss caused by corticosteroid-induced glaucoma: how to avoid it.
TLDR
The only clinical significance of steroid-induced elevation of intraocular pressure in response to corticosteroids is that such elevation of IOP may, in some cases, lead to nerve damage and cause visual disability, decreasing the quality of life. Expand
Iatrogenic glaucoma secondary to medications.
TLDR
The first step in the management is discontinuation of the drug, followed by medical, laser, and, if necessary, surgical intervention, in patients with a narrow irido-corneal angle. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 116 REFERENCES
Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids
TLDR
The use of oral glucocorticoids increases the risk of ocular hypertension or open-angle glaucoma in elderly patients in this age-group and monitoring of intraocular pressure may be justified. Expand
Inhaled and Nasal Glucocorticoids and the Risks of Ocular Hypertension or Open-angle Glaucoma
TLDR
Overall, current use of inhaled and nasal glucocorticoids was not associated with an increased risk of ocular hypertension or open-angle glaucoma, and this finding suggests that in these patients intraocular pressure monitoring may be warranted. Expand
CORTICOSTEROIDS AND INTRAOCULAR PRESSURE.
TLDR
The present study was undertaken to determine the effect of topical corticosteroids in the eye with primary open-angle glaucoma, and found that patients on long-term systemic Corticosteroid therapy showed significantly higher mean applanation pressures. Expand
ELEVATED INTRAOCULAR PRESSURE FOLLOWING CORTICOSTEROID EYE DROPS.
TLDR
This brief report is presented to alert physicians to the large and significant increases in intraocular pressure observed in so many of the patients studied. Expand
Ocular-hypertensive response to topical steroids in children.
TLDR
The ocular-hypertensive response to topical DMS in children occurs more frequently, more severely, and more rapidly than that reported in adults. Expand
Cellular sensitivity to glucocorticoids in patients with POAG. Steroid receptors and responses in cultured skin fibroblasts.
TLDR
The results suggest that a generalized cellular hypersensitivity to glucocorticoids is not intrinsic to POAG, and it is possible that environmental alterations and/or endogenous factors may influence the steroid responses observed in these patients. Expand
Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease.
TLDR
It is proposed that the mechanisms for steroid-induced lens opacities and raised IOP do not share the same genetic basis and should be advocated for careful ophthalmologic monitoring of pediatric patients receiving corticosteroids for IBD or any other condition. Expand
Treatment of Glaucoma with 3α,5β-Tetrahydrocortisol: A New Therapeutic Modality
TLDR
It is demonstrated that 3α,5β-THF, a naturally occurring steroid metabolite, is effective in lowering IOP in patients with POAG, and may represent a new therapeutic modality for the management of POAG. Expand
Inheritance of dexamethasone hypertension and glaucoma.
TLDR
It was shown that glaucoma does not represent a homogeneous single group with respect to the dexamethasone hypertensive response and that it could not be described exclusively by P H P H , instead it showed in addition P L P H and P L L P L as well. Expand
Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure.
TLDR
Intraocular pressure was measured in 54 pediatric patients with inflammatory bowel disease who were treated with oral prednisone for 1–104 months and the difference in mean IOP between the treated patients and age-matched controls was statistically significant. Expand
...
1
2
3
4
5
...